BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement

Reuters

Oct 29

BRIEF-<a href="https://laohu8.com/S/VOR">Vor Biopharma</a> Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement

Oct 29 (Reuters) - Vor Biopharma Inc VOR.O:

TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA
VOR BIOPHARMA INC - 100% PATIENTS ON TELITACICEPT ACHIEVE ≥2-POINT MG-ADL IMPROVEMENT
VOR BIOPHARMA INC - NO INJECTION SITE REACTIONS IN TELITACICEPT PATIENTS
VOR BIOPHARMA INC - TELITACICEPT SHOWS FAVORABLE PROFILE COMPARED TO PLACEBO

Source text: ID:nGNX7GVk07

Further company coverage: VOR.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2579839171"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579839171\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579839171?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-29 23:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579839171","market":"nz","top_or_hot":-1,"title":"BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/VOR\">Vor Biopharma</a> Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement</title></head><body><p><span>Oct 29 (Reuters)</span><span> - </span>Vor Biopharma Inc <span>VOR.O</span>:</p><ul><li><p>TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA</p></li><li><p>VOR BIOPHARMA INC - 100% PATIENTS ON TELITACICEPT ACHIEVE ≥2-POINT MG-ADL IMPROVEMENT</p></li><li><p>VOR BIOPHARMA INC - NO INJECTION SITE REACTIONS IN TELITACICEPT PATIENTS</p></li><li><p>VOR BIOPHARMA INC - TELITACICEPT SHOWS FAVORABLE PROFILE COMPARED TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7GVk07</span></p><p>Further company coverage: <span>VOR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-29 23:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/VOR\">Vor Biopharma</a> Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL Improvement</title></head><body><p><span>Oct 29 (Reuters)</span><span> - </span>Vor Biopharma Inc <span>VOR.O</span>:</p><ul><li><p>TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATA</p></li><li><p>VOR BIOPHARMA INC - 100% PATIENTS ON TELITACICEPT ACHIEVE ≥2-POINT MG-ADL IMPROVEMENT</p></li><li><p>VOR BIOPHARMA INC - NO INJECTION SITE REACTIONS IN TELITACICEPT PATIENTS</p></li><li><p>VOR BIOPHARMA INC - TELITACICEPT SHOWS FAVORABLE PROFILE COMPARED TO PLACEBO</p></li></ul><p>Source text: <span>ID:nGNX7GVk07</span></p><p>Further company coverage: <span>VOR.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA1R2:1","article_id":"2579839171","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579839171","pubTimestamp":1761752643,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL ImprovementOct 29 (Reuters) - Vor Biopharma Inc VOR.O:TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY P","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VOR":"Vor Biopharma Inc."},"translate_title":"BRIEF-Vor Biopharma表示，100%接受泰利西普治疗的患者MG-ADL改善≥2分","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VOR":0.9},"content_text":"BRIEF-Vor Biopharma Says 100% Patients On Telitacicept Achieve ≥2-Point MG-ADL ImprovementOct 29 (Reuters) - Vor Biopharma Inc VOR.O:TELITACICEPT DEMONSTRATES SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE IN 48-WEEK CHINA PHASE 3 OPEN-LABEL EXTENSION GENERALIZED MYASTHENIA GRAVIS DATAVOR BIOPHARMA INC - 100% PATIENTS ON TELITACICEPT ACHIEVE ≥2-POINT MG-ADL IMPROVEMENTVOR BIOPHARMA INC - NO INJECTION SITE REACTIONS IN TELITACICEPT PATIENTSVOR BIOPHARMA INC - TELITACICEPT SHOWS FAVORABLE PROFILE COMPARED TO PLACEBOSource text: ID:nGNX7GVk07Further company coverage: VOR.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}